1.	Phase II Study of Fazarabine and Filgrastim (G-CSF) in Chemotherapy Naive Patients with Recurrent or Metastatic Adenocarcinoma of the Pancreas (Summary Last Modified 08/1999) Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: NCCTG-964351, NCCTG-96-43-51
2.	Phase II Trial of Fazarabine in Patients with Refractory Metastatic and/or Unresectable Cancers of the Breast, Colon, and Testis (Summary Last Modified 11/91) Phase: Phase II Type: Treatment Status: Completed Age: over 18 Sponsor: NCI Protocol IDs: NCI-89-C-105, NCI-MB-241, NCI-T89-0045N, T89-0045
3.	Phase II Study of Fazarabine in Patients with Persistent or Recurrent Squamous Cell Carcinoma of the Head and Neck (Summary Last Modified 01/90) Phase: Phase II Type: Treatment Status: Completed Age: any age Sponsor: NCI Protocol IDs: SWOG-8912
4.	Phase II Study of Fazarabine in Patients with Metastatic Breast Cancer (Summary Last Modified 10/89) Phase: Phase II Type: Treatment Status: Completed Age: 16 and over Sponsor: NCI Protocol IDs: MDA-DM-89052, NCI-T89-0122C, T89-0122
5.	Phase II Master Protocol for Advanced, Recurrent Pelvic Gynecologic Malignancies: Fazarabine (Summary Last Modified 07/90) Phase: Phase II Type: Treatment Status: Completed Age: any age Sponsor: NCI Protocol IDs: GOG-26GG
6.	Phase II Study of Fazarabine in Patients with Advanced Measurable Colorectal Cancer (Summary Last Modified 06/97) Phase: Phase II Type: Treatment Status: Completed Age: 16 and over Sponsor: NCI Protocol IDs: MDA-DM-89107, NCI-T89-0212C, T89-0212
7.	Phase II Trial of Fazarabine in Patients with Metastatic Pancreatic or Periampullary Adenocarcinoma (Summary Last Modified 07/90) Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: MSKCC-90007, NCI-T90-0021C, T90-0021
8.	Phase II Study of Fazarabine in Patients with CNS Tumors (Summary Last Modified 08/90) Phase: Phase II Type: Treatment Status: Completed Age: no age specified Sponsor: NCI Protocol IDs: SWOG-8834
9.	Phase II Study of Intravenous Fazarabine in Patients with Advanced non-Small Cell Lung Cancer (Summary Last Modified 10/91) Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: MAYO-902401, NCI-T90-0062C, T90-0062
10.	Phase II Study of Fazarabine in Children with Recurrent Solid Tumors (Summary Last Modified 08/91) Phase: Phase II Type: Treatment Status: Closed Age: under 21 at diagnosis Sponsor: NCI Protocol IDs: CCG-0902
11.	Phase II Study of ARA-AC in Patients with Advanced Stage IV Nonsmall Cell Lung Carcinoma (Summary Last Modified 09/92) Phase: Phase II Type: Treatment Status: Completed Age: no age specified Sponsor: NCI Protocol IDs: SWOG-9138
12.	Phase II Study of Fazarabine in Patients with Poor-Prognosis Extensive Stage Small Cell Lung Cancer (Summary Last Modified 07/93) Phase: Phase II Type: Treatment Status: Completed Age: adult Sponsor: NCI Protocol IDs: SWOG-9213
13.	Phase I Study of ARA-AC/G-CSF for Advanced Cancer (Summary Last Modified 06/97) Phase: Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: MAYO-930101, NCI-T93-0155D, T93-0155
14.	Phase I Chemotherapy with Arabinosyl-5-Azacytidine in Patients with Solid Tumors or Lymphoma Phase: Phase I Type: Treatment Status: Closed Age: over 18 Sponsor: NCI Protocol IDs: MDA-DM-87002, NCI-T87-0023C, T87-0023
15.	Phase I Study of 1-B-D-Arabinofuranosyl-5-Azacytidine in Patients with Malignancies Phase: Phase I Type: Treatment Status: Completed Age: over 18 Sponsor: NCI Protocol IDs: NCI-87-C-24C, NCI-T86-0256N, T86-0256
16.	Phase I Chemotherapy with Fazarabine in Patients with Advanced Refractory Malignancies (Summary Last Modified 11/89) Phase: Phase I Type: Treatment Status: Closed Age: over 18 Sponsor: NCI Protocol IDs: OSU-87HO050, NCI-T87-0010C, T87-0010
17.	Phase I Study of Arabinosyl-5-Azacytidine in Pediatric Patients with Solid Tumors or Leukemia (Summary Last Modified 06/97) Phase: Phase I Type: Treatment Status: Completed Age: under 21 Sponsor: NCI Protocol IDs: NCI-87-C-127A, NCI-T87-0200N, T87-0200
18.	Phase I Study of Fazarabine Administered as a 24-Hour Continuous Infusion in Patients with Advanced Malignancies (Summary Last Modified 11/89) Phase: Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: WCCC-CO-8893, NCI-T88-0099C, T88-0099
19.	Phase I Trial of Fazarabine (Ara-AC) in Patients with Adult Acute Leukemia and CML in Blast Crisis (Summary Last Modified 09/90) Phase: Phase I Type: Treatment Status: Completed Age: 15 and over Sponsor: NCI Protocol IDs: MDA-DM-88051, NCI-T88-0112C, T88-0112
20.	Phase I Study of Fazarabine in Patients with Refractory Acute Leukemia or CML in Accelerated Phase (Summary Last Modified 03/89) Phase: Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: OSU-88HO312, NCI-T88-0222C, T88-0222
21.	Phase I Study of Prolonged Infusions of ARA-AC Alone and with G-CSF in Pediatric Patients with Relapsed or Refractory Leukemia or Lymphoma (Summary Last Modified 09/94) Phase: Phase I Type: Treatment Status: Closed Age: 21 and under Sponsor: NCI Protocol IDs: MSKCC-88144A6, NCI-T88-0262D, T88-0262
22.	Phase I Trial of Fazarabine in Children with Refractory Solid Tumors (Summary Last Modified 11/90) Phase: Phase I Type: Treatment Status: Closed Age: children Sponsor: NCI Protocol IDs: POG-8970
23.	Phase I Trial of Fazarabine in Children with Acute Leukemia (Summary Last Modified 11/90) Phase: Phase I Type: Treatment Status: Completed Age: under 20 Sponsor: NCI Protocol IDs: POG-9071